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Poster Session I S245at our institution from 1998 to 2009. Most received Cy/TBI (97%)
based regimens. Ph1 group was older, median age 42 yrs. vs. 38
yrs, p 5 0.02. The 2 groups were balanced in distribution of condi-
tioning regimen, donor and stem cell source, HLAmatch, CMV sta-
tus, and WBC at diagnosis. 73% of the Ph1 were transplanted in
CR1, vs. 37% of the Ph- (p 5 0.0001). There was no difference in
time to neutrophil/platelet engraftment, grade II-IV acute GVHD
(28% vs. 31%), and chronic GVHD (53% vs. 51%) in the Ph1 vs.
Ph- groups, respectively. 3-year cumulative incidence of non-relapse
mortality and relapse (as competing risks) were 24% vs. 29% (p 5
0.66) and 34% vs. 41% (p5 0.56), for Ph1 vs. Ph- patients, respec-
tively. With median follow-up of 36 and 48 months after transplant,
there was no difference in 3-year progression free survival (PFS) and
3-year overall survival (OS) from time of transplant for Ph1 and Ph-
patients (PFS: 40% vs. 32%, p5 0.53; OS: 48% vs. 34%, p5 0.36).
To adjust for more patients in the Ph1 group being transplanted in
CR1, we also assessed survival from time of ALL diagnosis. 3-year
PFS and OS from time of ALL diagnosis for the Ph1 and Ph- pa-
tients were similar (PFS 48% vs. 48%, p 5 0.67; OS 50% vs. 49%,
p 5 0.93). In subset analyses restricted to patients transplanted in
CR1, 3-year PFS and OS were also similar in Ph1 vs. Ph- patients
(PFS: 51% vs. 35% p 5 0.59; OS: 53% vs. 40% p 5 0.58, respec-
tively). In multivariable models, more recent year of transplant was
associated with an improvement in PFS (HR 0.88, 95% CI 0.77-
0.99, p 5 0.04), and a trend toward better OS (HR 0.88, 95% CI
0.77-1.01, p 5 0.06) in the Ph1, but not Ph- cohort. There was
a trend towards improved 3-year OS for all patients transplanted af-
ter 2001, the year of imatinib approval, (OS5 42%) vs. before 2001
(OS 5 26%), P 5 0.15. In competing risks regression modeling,
WBC at diagnosis . 100K and bone marrow graft (vs. PBSC)
were significant factors associated with increased relapse in Ph1 pa-
tients. Our data suggest that followingmyeloablative allo-SCT, Ph1
ALL patients have similar outcomes compared to patients with Ph-
ALL, even when adjusted for disease stage at time of transplant.248
REDUCED TOXICITY MYELOABLATIVE CONDITIONING REGIMENS (RTC)
COMPARED WITH STANDARD MYELOABLATIVE CONDITIONING PRIOR
TO ALLOGENEIC STEM CELL TRANSPLANTATION IN AML AND MDS;
RTC HAS MORE FAVORABLE TOXICITY PROFILE BUT MORE LIMITED
LEUKEMIA CONTROL IN ADVANCED DISEASE
Shimoni, A., Rand, A., Shem-Tov, N., Volchek, Y., Yerushalmi, R.,
Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer, Israel
Allogeneic stem cell transplantation (SCT) is a curative therapy
for patients (pts) with AML and MDS. Standard myeloablative con-
ditioning (MAC) is associated with high rates of non-relapse mortal-
ity (NRM). Reduced-intensity conditioning reduces NRM but
relapse rates are higher. Reducing toxicity without compromising
SCT efficacy could be of a significant benefit. Novel reduced toxicity
myeloablative regimens (RTC) such as fludarabine with myeloabla-
tive doses of busulfan or treosulfan were designed to achieve this
goal, however their relative merits in different settings are not well
established. We analyzed SCT outcomes in a group of 252 pts
[AML-199 (66 secondary), MDS-53], median age 50 (17-76), given
SCT from related (n 5 144) or unrelated donors (n 5 108). Disease
status at SCT was defined as early (n5 81), intermediate (n5 54) or
advanced (n 5 117) by CIBMTR criteria. Eligible pts were given
MAC (BuCy, n5 90). Pts considered at high risk for NRM, but still
eligible for myeloablation were given RTC (n5 162). This group in-
cluded older pts (median age 55 Vs 39 years), more pts with comor-
bidity index . 2 (19% Vs 5%) and more unrelated donors. With
median follow-up of 36 months (1-129), 119 are alive, 52 had
NRM and 81 died of relapse. The 5-year overall survival (OS) is
41% (95CI, 34-48). It was 43% and 40% after MAC and RTC, re-
spectively (p 5 NS). NRM was 21% in both and relapse was 36%
and 39%, respectively (p5NS). Multivariable analysis (MVA) iden-
tified advanced disease as the major adverse factor for OS (HR 2.3, p
\ 0.001). Age . 50 and MAC were risk factors for NRM and ad-
vanced disease for relapse. The conditioning regimen had prognostic
significance in certain settings. Pts with MDS/2AML had better OS
after RTC than MAC; 49% and 37%, respectively (p5 0.07). MAC
(HR 1.9, P 5 0.03) and comorbidity index (HR 1.6, p 5 0.05) were
adverse prognostic factors. These pts were particularly more suscep-
tible to NRM with MAC. Pts with early AML had a trend for betterOSwithRTC; 75%and 47%, respectively (p5NS).MAChad a sur-
vival advantage in pts with intermediate-advanced disease, 45% and
22%, respectively (p5 0.06). This was due to higher relapse rate af-
ter RTC, 58% and 33%, respectively (p5 0.02). In conclusion, RTC
allows SCT in pts at higher risk for NRM with outcomes that are
similar to MAC in eligible pts. RTC may have an advantage in
MDS/2AML and possibly in early AML due to reduction of
NRM. However, MAC has an advantage in more advanced AML
due to better leukemia control.249
MULTI-DIMENSIONAL RESISTANCE PHENOTYPE ALLOWS QUIESCENT
LEUKEMIC STEM CELLS RESIDING AFTER TYROSINE KINASE INHIBITOR
TREATMENT TO ESCAPE FROM IMMUNOLOGICAL INTERVENTIONSWITH
ALLOREACTIVE T CELLS AND NK CELLS
Jedema, I., vanDreunen, L., Hagedoorn, R.S., Falkenburg, J.H.F. Leiden
University Medical Center, Leiden, Netherlands
Chronic myeloid leukemia (CML) is well responsive to various
therapeutic strategies, including tyrosine kinase inhibitors (TKI)
and allogeneic stem cell transplantation combined with donor lym-
phocyte infusion (DLI). Although initial complete responses are fre-
quently achieved, recurrenceof the disease is a commonphenomenon
occurring sometimes years after the therapeutic intervention(s). This
suggests that an initially undetectable subpopulation of leukemic pre-
cursor cells is capable of escaping therapy. In this study, we investi-
gated in detail the phenotype and apoptosis gene expression
fingerprint of this subpopulation of CML precursor cells residing af-
ter TKI treatment and immunological interventions with high affin-
ity cytotoxic donor T cells or NK cells. CD341 positive CML cells
were isolated from bone marrow and the number, phenotype, and
proliferative status of the CML cells residing after therapeutic inter-
vention(s) were measured by quantitative flowcytometry. Although
the majority of CML precursor cells and their malignant progeny
were efficiently targeted, a small subpopulation of non-dividing
CD34 bright cells, comprising on average 0.05-0.2% of the initial
CD341 population, showed cross-resistance to the different strate-
gies. In the absence of therapeutic pressure these cells were capable
of producingmalignant progeny. Phenotype analysis showed inferior
expression of HLA-class I and several adhesion molecules crucial for
the formationof a high avidity interactionwith immune effector cells,
includingCD54, CD58 andCD49d.Next, we compared the apopto-
sis gene expression fingerprint of this resistant subpopulation with
the profile of total CD341CMLprecursor cells and their proliferat-
ing malignant offspring using a quantitative array PCR containing
probes for 86 apoptosis-related genes (SABiosciences). This genetic
profiling revealed significant downregulation (4-182 fold) of crucial
players of the different main apoptosis pathways, including caspase-
3 and -8, Fas, TNFR, and different association molecules like
FADD, TRADD, and TRAFs, and a 4.8-6.2 fold upregulation of
the most important inhibitor of the death receptor pathway c-FLIP
(CFLAR). Interestingly, we observed a 55 fold downregulation of
the TKI-targeted fusion gene partner Abl1. These data show that
a subpopulation of CML precursor cells with potential self-renewal
capacity harbors a multi-dimensional resistance phenotype allowing
them to escape from different therapeutic strategies.250
SUCCESSFUL MANAGEMENT OF REFRACTORY/RECURRENT ACUTE MYE-
LOID LEUKEMIA BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION AND PROPHYLACTIC IMMUNOTHERAPY
Wang, J.-B., Wu, T., Da, W.-M., Sun, Y., Zhao, Y.-L., Cao, X.-Y.,
Yin, Y.-M., Lu, Y., Zhou, J.-R., Gao, Y.-Q., Zhang, J.-P., Luo, R.-
M., Zhang, Y.-C., Ji, S.-Q., Lu, D.-P., Tong, C.-R. Beijing Daopei
Hospital, Beijing, China
Our previous study has shown that donor’s dendritic cell-primed
cytokine-induced killer cell (DC-CIK) is a safe and effective thera-
peutic mean in management of early leukemia recurrence after allo-
geneic hematopoietic stem cell transplantation (HSCT) (JB Wang,
et al.ASH 2008). In present clinical study, the efficacy of refrac-
tory/recurrent acute myeloid leukemia (AML) salvaged by HSCT
and prophylactic immunotherapy is evaluated. From September
S246 Poster Session I2006 to April 2010, total 44 patients with refractory/recurrent AML
were enrolled. The median age was 29 (2 to 51) years old. The me-
dian blasts in bone marrow (BM) were 36% (20% to 92%) before
conditioning. The donors were identical siblings (6) or unrelated
ones (9) or haploidentical family members (29). Conditioning regi-
ments were individualized according to patients’ status. Usually,
the regimen with high-dose cytarabine plus BUCY/CYTBI was
used (20). The patients with impaired organ function received above
regimen except using fludarabine instead of cyclophosphamide (16).
For the recipients with more than 40% blasts in BM, in order to re-
duce leukemia burden, melphalan (2) was added into above regimen
or FLAG that followed by reduced-intensified BUCY (6) was em-
ployed. GVHD prophylaxis was reported previously (DP Lu et al.,
Blood 2006;107:3065). Prophylactic immunotherapy including
DLI, DC-CIK, NK cells, IL-2, IFN-a, thymosin was used in the pa-
tients (11) who were lack of GVHD 120 days post-HSCT. All but
two patients attained durable engraftment. The incidence of grade
II to IV aGVHD and cGVHD were 32.2%, 59.1%, respectively.
With median follow-up 11 (1-46) months, the relapse rate was
25.1%. Thirty of 44 (68.2%) patients have been in complete remis-
sion since salvaged HSCT. One-year disease-free survival and over-
all survival were 68.5%, 70.4%, respectively. Our clinical results
have shown that the combination of salvaged HSCT and prophylac-
tic immunotherapy is a promising modality for treatment of refrac-
tory/recurrent AML, even with high leukemia burden.251
BONE MARROW STOMA SECRETES A SOLUBLE FACTOR THAT PROTECTS
LEUKEMIA CELLS FROM CYTARABINE INDUCED APOPTOSIS BY BLOKING
ENT ACTIVITY
Macanas, P.1, Leisewitz, A.1, Broekhuizen, R.1, Chomali, V.2,
Leisewitz, F.2, Ramirez, P.1, Cautivo, K.2, Kalergis, A.2,
DiPersio, J.F.3, Nervi, B.1 1Pontificia Universidad Catolica de Chile,
Santiago, Chile; 2Pontificia Universidad Catolica de Chile, Santiago,
Chile; 3Washington University School of Medicine, Saint Louis
Introduction: Despite a high response rate to chemotherapy, the
vast majority of patients with AML are destined to relapse due to re-
sidual disease in the bone marrow (BM). The tumor microenviron-
ment is increasingly being recognized as a critical factor in
mediating cancer development and drug resistance. Leukemia cell
mobilization in vivo by the CXCR4 inhibitor, AMD3100 induced
chemosensitization to AraC, which translated into a significant
survival advantage in mice (Nervi et al., 2009).
Objectives: In vitro evaluation of the mechanisms involved in leuke-
mia cell chemoprotection to AraC-induced apoptosis mediated by
bone marrow stroma.
Results: A leukemia mouse cell line generated by knocking in the
human PML-RARa cDNA (APL) was cultured with or without
BM stroma supernatant (BMS; obtained from the BM stroma cell
line M2-10B4) and treated with AraC for 24 hours. FACS analysis
showed that BMS induced a significant and selective chemoprotec-
tion to Arac (25% vs 65% apoptosis respectively). There was no pro-
tection observed with other cytotoxic agents such as cisplatin,
etoposide, 5-FU, Gemtuzumab or radiotherapy. BMS did not mod-
ify the APL cell cycle status (CFSE, PI). AraC enters the cell via the
ENT (equilibrative nucleoside transporter). To verify whether the
soluble factor exerts an effect over the ENT, the activity of thismem-
brane transporter was investigated in samples with APL cultured
alone or cultured with BMS for 24 hours by the incorporation of ra-
dioactive adenosine. Interestingly, the data showed there is a 50% re-
duction in ENT activity, without changes in ENT mRNA or ENT
protein expression. This effect was confirmed by using the ENT in-
hibitor, NBMPR. Detection of caspase-3 activity was performed to
confirm apoptosis mediated by AraC, and the results confirmed
that the chemoprotection by the soluble factor causes a significant
reduction of caspase-3 activity and apoptosis. Cytotoxicity studies
by the MTT assay revealed that the inhibition of ERK (U0126) in
APL cells cultured with BMS significantly reverted the protection
and sensitized the cells to AraC treatment.
Conclusion: The BM stroma secretes a soluble factor(s) that
significantly protect APL cells from AraC-induced apoptosis by par-
tially blocking ENT activity and by activation of MAPK (ERK) in-
tracellular signaling pathways associated with cell survival andproliferation. Strategies that modify leukemia/BM microenviron-
ment interaction may potentially improve leukemia patient
outcomes.252
IMPROVED SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA
WITH NORMAL CYTOGENETICS AND FLT3-ITD MUTATION AFTER ALLO-
GENEIC HEMATOPOIETIC CELL TRANSPLANT: CONCURRENT NPM1
MUTATION NOT ASSOCIATED WITH BETTER OUTCOMES
Loh, Y., How, G.F., Hwang, W., Linn, Y.C., Goh, Y.T., Diong, C.P.,
Wong, G.C., Lim, L.C. SingaporeGeneral Hospital, Singapore, Singapore
Background: Acute myeloid leukemia (AML) with normal cytoge-
netics (CN) is a heterogenous disease with an increasing number
of molecular mutations demonstrated in recent years. The FLT3 in-
ternal tandem duplication (FLT3-ITD) has been associated with ad-
verse outcomes; while outcomes of NPM1-mutated AML have been
favorable. The interplay between the various mutations remains to
be fully elucidated and hence the decision on which patients with
CN AML would benefit from an allogeneic transplant in first
complete remission (CR1) is in flux.
Aims: We undertook an analysis of the outcomes of adult patients
with AML to determine the impact of FLT3 ITD and NPM1 on
outcomes. We assessed whether complete response rate (CR), re-
lapse rate, OS and cumulative probability of relapse following che-
motherapy, autologous or allogeneic transplant are affected by the
presence of these mutations.
Methods:This is a retrospective analysis of adult CN AML patients
treated between 2003 and 2008. In our center, patients in CR1 below
age 50 years who have a sibling donor are usually offered an alloge-
neic transplant. Those who do not, either undergo consolidation
with high dose cytarabine or an autologous transplant. Patients
with poor risk features such as needing more than one cycle to
achieve CR are considered for an unrelated donor allograft if a suit-
able donor is found.
Results: Fifty-three patients with median age 51 years (15-61 years)
were treated. Of these, 20 underwent autologous, 9 sibling and 7
URD transplants while the rest received chemotherapy alone. The
frequency of mutations was FLT31/NPM1 (n 5 12) FLT1/
NPM- (n 5 10), FLT-/NPM1 (n 5 8), FLT-/NPM- (n 5 12), ei-
ther unknown (n 5 11). At a median duration of follow up of 22
months (0-78months) the probability of OS among FLT31 patients
was significantly different based on treatment type: sibling 66.7% vs.
URD 20.8% vs. autologous 13.8% vs. chemotherapy 0% (p \
0.001). Among FLT31/NPM- patients, the overall survival based
on treatment type: sibling 100% vs. auto and chemo 0% (p 5
0.001) while for FLT1/NPM1 patients: allograft 50% vs. autolo-
gous 22% (p 5 0.012). The numbers of patients with FLT-/
NPM1 were too few to analyze.
Conclusions: The presence of FLT3 ITD confers an adverse prog-
nosis on patients with CN AML but our data suggests a sibling allo-
graft may ameliorate this. The concurrent presence of NPM1
mutation with FLT3 does not appear to abrogate the adverse impact
and such patients should also be offered an allograft.253
MULTIPLEX REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION
AS A DIAGNOSTIC DEVICE AND PREDICTIVE OF SURVIVAL FOR ACUTE
LEUKEMIA
Park, J.S., Ahn, M.S., Jeong, S.H. Ajou University School of Medicine,
Suwon, Kyunggi-do, Korea
In addition to conventional G-banding technique, multiplex re-
verse transcriptase polymerase chain reaction (mRT-PCR) could
be applied for the documentation of cytogenetic aberrations in diag-
nosing acute leukemia. The bone marrow samples from 276 patients
with acute leukemia were examined with mRT-PCR and the results
were compared with conventional cytogenetics with regard to com-
patibility and survival outcome. Concordance rate between G-band-
ing and mRT-PCR was 49.5%. G-banding did not detect
chromosomal aberrations that were documented with mRT-PCR
in 20.3% of patients as opposed to 27.9% of patients, vice versa. Fa-
vorable cytogenetic aberrations such as t(15;17), t(8;21), and inv(16)
